Nausea

FDA approves new drug for cancer patients getting chemotherapy

Published in Medical Letter on the CDC and FDA, April 20th, 2003

The U.S. Food and Drug Administration (FDA) has announced the approval of a new drug called Emend (aprepitant), to be used in combination with other antinausea and antivomiting drugs for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of chemotherapy known to cause these problems, including high-dose cisplatin.

Emend is the first FDA-approved treatment that prevents the delayed nausea and vomiting symptoms that many patients experience more than 24 hours after receiving chemotherapy. Chemotherapy is often very distressing for cancer patients due to severe nausea and vomiting. These symptoms can be severely debilitating,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2003-04-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry